Krensavage Asset Management LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 50.0% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,000 shares of the biopharmaceutical company’s stock after acquiring an additional 2,000 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.4% of Krensavage Asset Management LLC’s holdings, making the stock its 14th biggest holding. Krensavage Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $3,741,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. California State Teachers Retirement System lifted its position in shares of Regeneron Pharmaceuticals by 63,274.2% during the 2nd quarter. California State Teachers Retirement System now owns 97,723,683 shares of the biopharmaceutical company’s stock worth $60,934,625,000 after purchasing an additional 97,569,482 shares during the last quarter. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at $5,682,636,000. Norges Bank acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $1,012,296,000. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after buying an additional 1,144,887 shares in the last quarter. Finally, Nuveen LLC raised its stake in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after buying an additional 835,240 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.
Insider Transactions at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president directly owned 12,003 shares of the company’s stock, valued at $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,146 shares of company stock worth $3,432,488 in the last three months. Corporate insiders own 6.97% of the company’s stock.
Regeneron Pharmaceuticals Stock Performance
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $12.81 earnings per share. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.
Wall Street Analyst Weigh In
REGN has been the subject of several analyst reports. HSBC lowered their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada boosted their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Guggenheim upped their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. Fourteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $800.36.
Check Out Our Latest Analysis on Regeneron Pharmaceuticals
More Regeneron Pharmaceuticals News
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Regeneron’s presentation at the Wells Fargo Healthcare Conference may provide investors with additional detail on its pipeline, commercial portfolio and strategy. However, the available report is a transcript and does not identify a new market-moving announcement. Wells Fargo conference transcript
- Neutral Sentiment: Recent fund commentary is mixed: Harbor Funds discussed the stock’s bullish potential, while American Century Investments reported selling its Regeneron position. These manager opinions may influence sentiment but do not change the company’s fundamentals. Harbor Funds commentary American Century fund sale
- Negative Sentiment: Several firms reiterated that investors who purchased REGN between August 1, 2025 and May 15, 2026 may seek lead-plaintiff status by September 14, 2026. The allegations focus on whether Regeneron adequately disclosed the protocol and risks of the Phase 3 fianlimab-Libtayo melanoma study, which ultimately failed; notices cite an earlier decline of roughly $102 per share from the class-period high. The repeated announcements increase litigation visibility and could keep a risk discount on the shares. Hagens Berman class-action notice Robbins Geller deadline notice
- Negative Sentiment: Analyst commentary also highlighted reasons to avoid REGN, including recent underperformance versus the broader market, adding to the cautious tone around the shares. Reasons to avoid REGN
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.
Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
